The Japanese drugmaker raised its full-year revenue forecast after reporting ¥574.78 billion in Q1 sales.
Daiichi Sankyo reported first-quarter revenue of ¥574.78 billion, supporting an upward revision to its fiscal 2026 guidance. The company now expects global revenue to reach 2.34 trillion yen, up from a prior forecast of 2.28 trillion yen.
The revision reflects stronger-than-anticipated sales performance in the quarter. The previous guidance was issued in May 2026, with the new target representing a 2.6% increase.
No immediate market reaction was disclosed in the release.